Biden DXM Bill Includes Age Limit, Bulk Ingredient Scheduling
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association backs Sen. Joe Biden's proposal to set a nationwide age limit on purchases of dextromethorphan-containing OTC drugs, but the group differs with the bill's approach to regulating bulk sales of raw DXM
You may also be interested in...
“Snurf” Abuse Reports Revive Interest In DXM Bills
A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant
Dextromethorphan Under Scrutiny For Possible International Regulation
The World Health Organization will consider recommending dextromethorphan and nine other drugs for potential international restrictions, and will base its decisions in part on information provided by FDA
Lingering Side Effects Of Cough/Cold Issues Drive CHPA 2008 Agenda
In the coming year, the Consumer Healthcare Products Association will work to emphasize to Congress the safety and efficacy of OTC drugs approved under FDA's monograph system